Peer-Review Record
Enhancer RNA AL928768.3 from the IGH Locus Regulates MYC Expression and Controls the Proliferation and Chemoresistance of Burkitt Lymphoma Cells with IGH/MYC Translocation
Int. J. Mol. Sci. 2022, 23(9), 4624; https://doi.org/10.3390/ijms23094624
by
Ekaterina Mikhailovna Stasevich 1, Aksinya Nicolaevna Uvarova 1, Matvey Mikhailovich Murashko 2,3, Elmira Ramilevna Khabusheva 1,4, Saveliy Andreevich Sheetikov 5, Vladimir Sergeyevich Prassolov 1,4, Dmitriy Vladimirovich Kuprash 1,2, Denis Eriksonovich Demin 2,*
and Anton Markovich Schwartz 1
and Anton Markovich Schwartz 1Reviewer 1:
Anonymous
Reviewer 2:
Anonymous
Int. J. Mol. Sci. 2022, 23(9), 4624; https://doi.org/10.3390/ijms23094624
Submission received: 27 February 2022
/
Revised: 16 April 2022
/
Accepted: 18 April 2022
/
Published: 21 April 2022
(This article belongs to the Special Issue Non-coding RNAs in Pathogens and Associated Diseases)
Round 1
Reviewer 1 Report
The findings appear to be interesting. Specific points that the authors need to address are as follows:
- The effect of AL928768.3 knockdown on the proliferation should be analyzed by colony forming assay. The effcts on survival should be analyzed by different assays to measure apoptosis.
- How overexpression and knockdown of eRNA AL928768.3 produced corresponding changes in the expression of MYC proto-oncogene should be analyzed in detail.
- A limited in vivo study will greatly increase the impact of the findings.
- The authors should provide their own justification and relevance of the study. This will help the readers to understand the importance of the paper.
- Minor typographical errors were found throughout the manuscript and should be corrected.
Author Response
Please see the attachment.
Author Response File: 
Author Response.pdf
Reviewer 2 Report
Title: Enhancer RNA AL928768.3 from IGH locus regulates MYC expression and controls proliferation and chemoresistance of Burkitt lymphoma cells with IGH/MYC translocation Authors: E.M. Stasevich, A.N. Uvarova, M.M. Murashko et al. The Authors have performed an interesting study and obtained a set of novel, important results. The submitted manuscript is well written and nicely illustrated. There are some minor remarks: The Authors should mention an efficiency of transfection by means of electroporation they achieved. Whether it was checked? If yes, which percent of the treated cells became positive? It is unclear why the Authors used crizotinib to demonstrate the Burkitt lymphoma cell resistance to chemotherapy. This drug is not used for treating Burkitt lymphoma but only against anaplastic large cell lymphoma (see given ref [35]). Instead, the Authors could use cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate or cytarabine that are conventionally used in chemotherapy of Burkitt lymphoma. So, the Authors should better explain why they preferred crizotinib in their model. Fig. 6 is not very persuading. The reliable difference takes place only under the maximal drug concentration that is rather high (5 microM) and clinically non-achievable. The Authors should explain why the reliable difference was not observed under the lower drug concentrations.Author Response
Please see the attachment.
Author Response File: Author Response.pdf
